AstraZeneca’s $7B bet on Daiichi Sankyo’s antibody drug conjugate pays off with pivotal data to back their regulatory pitches
Buoyed by the performance of its oncology drugs, in March AstraZeneca chief Pascal Soriot bet big to partner with Daiichi Sankyo on its experimental breast cancer drug, with $1.35 billion upfront in a deal worth up to roughly $7 billion. On Wednesday, the Japanese drugmaker said the therapy had cleared a pivotal mid-stage study, paving the way for regulatory submissions in the first half of fiscal 2019.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.